Allstate reports Q1 2026 results today with investors showing a clear tilt toward protection, even as the underlying borrow market remains relaxed.
The options market is the sharpest signal heading into the print. The put/call ratio has climbed to 1.23, running nearly 1.75 standard deviations above its 20-day average of 1.14 — the most defensive posture of the past several weeks. That elevated reading suggests traders are paying meaningfully more for downside cover ahead of today's release. The stock itself has pulled back 1.9% on the day to $212.33, though it remains up roughly 4.7% over the past month.
Short interest has been building, and the pace of that build is worth noting. SI has risen 16% over the past month to 2.8% of the free float — still a modest absolute level, but the directional move accelerated sharply in mid-April, with shares short jumping from roughly 5.8 million to 7.3 million in the space of two weeks. Despite that increase, the borrow market tells a far calmer story: cost to borrow has eased to 0.39%, down about 19% over the past month, and availability remains very loose — suggesting the new short positions are being established without any friction in the lending pool. Borrow conditions do not point to squeeze risk.
The debate heading into the print centres on whether Allstate's recovery in personal auto underwriting can hold against growing competitive and catastrophic-loss headwinds. Bulls point to the positive trajectory in policies-in-force — up 1.3% with a stronger 2.8% monthly gain — and a track record of beating estimates that ranks in the 87th percentile on EPS surprise. EPS momentum scores are also solid, sitting in the 70th–77th percentile range on both 30- and 90-day readings. Bears counter that the combined ratio of 89.4% trails the company's own 95% long-term target, raising questions about underwriting discipline, while competitive pressure on personal lines pricing threatens to compress margins just as the growth recovery accelerates. Analyst activity in recent weeks has been cautious rather than directional: Wells Fargo and Barclays both made token target raises in early April while holding neutral and underweight ratings respectively, with the consensus mean target at $239.90 implying around 13% upside from current levels. The Street is split, not aligned.
CEO Tom Wilson sold roughly $5.5 million in shares across two tranches in early-to-mid March at prices between $207 and $213 — closely bracketing the current price — a detail that doesn't materially change the setup but reduces the insider-conviction angle. Peer performance on the week has been mixed: TRV gained nearly 3% while PGR and ACGL both dipped. ALL underperformed the group modestly.
Today's print is therefore less a test of whether Allstate is growing and more a test of whether that growth is arriving at a combined ratio and loss-cost trajectory that justifies paying the current multiple — with a defensive options posture already priced in on either side of the number.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
